Ozempic Face: The Unexpected Ripple Effect of Ozempic's Popularity, "Volufiline" Gives a Boost to a Long-Established British Company

Beyond the Weight Loss Boom, Another Concern Emerges

Losing weight is a joy. However, when looking in the mirror, the impression of the cheeks and eyes seems different from before.

As interest in GLP-1-related drugs grows, changes in appearance like these have also gained attention. This includes the phenomenon known as "Ozempic Face," characterized by a reduction in facial plumpness and sagging.

This concern has created business opportunities for companies other than pharmaceutical manufacturers.

Featured in the Brisbane Times on October 19, 2026, is the British chemical company Croda. Their cosmetic ingredient "Volufiline" has attracted the interest of consumers concerned about their facial appearance post-weight loss, leading to increased sales.

However, there are two ways to interpret this news. One is the story of a company linking existing technology with new demand. The other is the question of how much of the beauty expectations spreading on social media should be accepted as scientific fact.

"Ozempic Face" Cannot Be Explained by the Drug Name Alone

First, let's clarify the meaning of the term "Ozempic Face."

The American Academy of Dermatology explains that after using GLP-1-related drugs, some people may notice a decrease in facial volume, sagging skin, and wrinkles. One of the reasons behind this is rapid weight loss, and the changes in facial appearance when losing weight quickly do not occur only in those who use specific drugs.

Thus, interpreting this term as "Ozempic causes facial aging" is not appropriate. It is necessary to separate weight changes from the effects of the drug.

In Japan, the approved indication for Ozempic is type 2 diabetes. Even if there are drugs with the same ingredients, the applications differ by product. The expression "weight loss drug" seen in overseas articles cannot be directly applied to its use in Japan.

The health benefits gained from treatment and concerns about appearance are separate issues. If appearance becomes a concern, the basic approach should be to consult the treating physician rather than discontinuing the prescribed medication on one's own judgment.

Not a New Invention, but a "Rediscovery" of an Old Ingredient

Volufiline is not a newly invented ingredient.

In a 2025 announcement, Croda Japan introduced it as a long-standing cosmetic ingredient. Its display name is "Anemarrhena Asphodeloides Root Extract, Hydrogenated Polyisobutene." It is a raw material for cosmetics containing plant-derived ingredients.

The company has explained its role in adipocyte differentiation and lipid accumulation, promoting its use for body care as well as for areas like the eyes and cheeks.

What should be noted here is that it's not just the raw material itself that has changed.

Even existing technology can take on different value if consumer concerns and the ways they learn about products change. In the case of Volufiline, the interest in facial volume and the use of short videos on social media to convey usage and appearance changes have become the connection point.

Croda itself positions finding new applications for existing ingredients as a form of technological innovation.

Sales Up 270%—Beauty Buzz Reaches Ingredient Manufacturers

According to the Brisbane Times, Volufiline's sales increased by 270% in the first half of 2026, with over 150 companies moving to adopt it in their products. Additionally, videos with related tags on TikTok Shop in the U.S. garnered 200 million views over 12 months.

These figures are reported by the paper, and the number of views does not equate to the number of buyers or those who felt the effects. Nonetheless, the fact that the name of a beauty ingredient itself has become known to consumers is significant.

Typically, consumers see cosmetic brands or product names and are not aware of the ingredient manufacturers behind them. However, on social media, there is behavior where specific ingredient names are searched to find products.

As a result, consumer interest reaches the source of the ingredients through cosmetic brands.

Croda's official communications also explain that requests from customers wanting to use the company's ingredient trademarks have tripled in the past year. While this is not a sales indicator for Volufiline alone, it indicates that the recognition of ingredient names is becoming valuable for business.

However, the success of a single ingredient does not mean the entire company's restructuring is complete. This news should be read as an example of a new growth opportunity arising for a long-established company.

What Does the Number "92% Composition" Mean?

Against this backdrop of interest, The Ordinary is selling a serum called "Volufiline 92% + Pal-Isoleucine 1%."

The official product description introduces it as a product that improves the appearance of areas like under the eyes and cheeks, where volume loss is noticeable.

However, one should be cautious about the "92%" figure.

Volufiline is a trademarked ingredient containing plant-derived components. The label "Volufiline 92%" cannot be interpreted as meaning that 92% of a specific active molecule of plant origin is included.

Furthermore, a high composition rate alone does not mean it is more effective than other products. It is necessary to check the formulation as a finished product and what kind of tests were evaluated.

Cosmetic numbers may seem easy to compare. However, without understanding "what proportion it is," the size of the numbers can be misleading.

Reactions on Social Media Are Divided Between "Changed" and "Uncertain"

On social media, voices of expectation and cautious voices coexist.

In skincare-related threads on the overseas forum Reddit, there was a post from someone who felt a difference in the appearance of lines around the mouth. However, the poster also increased their water intake during the same period, so it might be due to perception or other factors.

Another user felt changes around the eyes and continued using it, but they were unsure if it was due to moisturizing or Volufiline itself.

Conversely, there were posts from people who tried multiple brands but did not feel any difference other than moisturizing.

These are not direct reactions to the article but summaries of user posts about Volufiline in general. The usage conditions of the posters, the conditions of the photos, and the authenticity of the products cannot be independently verified, nor do they represent the overall evaluation of users.

Nevertheless, they provide clues to understanding the interest on social media. The expectation to change the facial impression through daily skincare without injections is strong. However, even those who felt a difference may not be able to determine the reason.

There is a significant gap between the impression "it worked well" and the medical explanation "lost facial fat increased."

Sales and Proven Effectiveness Are Not the Same

The most easily confused aspect of the Volufiline topic is the explanation of the ingredient's action and the effect when applied to the face.

Even if changes related to lipid accumulation are observed in cell-based tests, that alone cannot conclude that the cheeks of people who apply the cosmetics will regain volume.

How far the ingredient penetrates the skin, the extent of changes that occur, whether it can be distinguished from moisturizing effects, and how long the effects last—these points need to be confirmed to explain the effects on the face.

Based on the manufacturer materials and product descriptions reviewed, it is not possible to determine that there is an established therapeutic effect on facial changes after weight loss due to GLP-1-related drugs.

Additionally, Croda itself explains that Volufiline is not a finished product but a cosmetic ingredient to be used in professionally designed formulations.

The self-use of ingredients seen on social media is not the same as using cosmetics evaluated and designed as finished products. The straightforward expression "topical filler" should not be taken as a guarantee of the same results as injection treatments.

What Japan Should Consider Is the Mechanism of Selling Expectations for the Face

For Japan, this is not just a rare beauty news story from overseas.

Croda Japan has already introduced its use for areas like the eyes, cheeks, and lips. The consumer behavior of searching for ingredient names that became popular overseas and looking for Korean cosmetics or imported products is also easy to connect with.

What is needed here is not to uniformly deny trends. It is to discern whether product descriptions refer to the smoothness or plump impression of the skin surface or claim changes to the tissue itself.

If considering a purchase, it is important to check not only the composition rate but also the description of the finished product, the area of use, the method of use, and the subjects of the tests. If changes after weight loss are a concern, there is an option to consult a doctor, including weight changes and skin condition, rather than trying to solve it with cosmetics alone.

Attention should also be paid to the structure where people who lost weight for health reasons now face new anxieties because "the face looks different than before."

The desire to enhance appearance should be respected. At the same time, it is important that the results of treatment and personal satisfaction are not obscured by the constantly presented "ideals" in beauty.

Calmly Observing the Tailwind for a Long-Established Company

The case of Croda shows that new value does not necessarily arise from new inventions. Even long-held ingredients can become central to demand again due to societal changes.

However, the business success does not prove the effectiveness of cosmetics.

By reading separately the increase in sales, attention on social media, user feedback, and medical backing, both the interest and limitations of this news become apparent.

The changes brought about by weight loss drugs extend beyond pharmaceutical companies. Whether what the beauty industry offers becomes a satisfactory option or merely leads expectations is questioned by the explanations and verifications that match the scale of the topic.

Sources and References

1. Brisbane Times: Croda's business trends, 270% increase in Volufiline sales, number of adopting companies, TikTok-related viewership scale, etc.
   https://www.brisbanetimes.com.au/business/companies/the-ozempic-face-discovery-that-revived-a-fading-giant-20261019-p615bg.html

2. Croda Official: Business strategy of re-evaluating existing ingredients, increase in requests to use ingredient trademarks, explanation that it is a cosmetic ingredient used in specialized formulations.
   https://www.croda.com/en-gb/media-hub/life-at-croda/volufiline-a-heritage-beauty-active-with-a-new-momentCroda

3. Croda Japan Press Release: Introduction in Japan, display name of ingredients, actions and uses explained by the manufacturer. It is a company announcement and should be referenced separately from independent clinical evaluations.
   https://prtimes.jp/main/html/rd/p/000000019.000088166.htmlCroda Japan K.K. Press Release

4. American Academy of Dermatology: GLP-1-related drugs and changes in skin and facial appearance, relationship with rapid weight loss, consultation with healthcare providers.
   https://www.aad.org/public/everyday-care/skin-care-secrets/prevent-skin-problems/glp1-drugs-and-side-effectsaad.org

5. The Ordinary Official: Product name of serum containing 92% Volufiline, composition details, uses indicated by the manufacturer.
   https://theordinary.com/en-au/volufiline-92-pal-isoleucine-1pct-plumping-serum-100724.htmlThe Ordinary

6. Reddit: Thread discussing experiences with Volufiline. Summary of voices feeling changes, indistinguishable from moisturizing, and not feeling changes. Personal anecdotes and not proof of effectiveness.
   https://www.reddit.com/r/45PlusSkincare/comments/1tn5u4q/has_anyone_here_actually_seen_noticeable_results/reddit.com

7. PMDA: Risk management plan for Ozempic. Confirmation that the indication in Japan is for type 2 diabetes.
   https://www.pmda.go.jp/RMP/www/620023/aa30c8e9-d50c-4186-9fbf-05f50aad8502/620023_2499418G1028_013RMP.pdf